Neuraxis reports fourth quarter and fiscal year 2023 financial results

Carmel, ind., april 09, 2024 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended december 31, 2023.

NRXS Ratings Summary

NRXS Quant Ranking